Mark C. McKenna
Sits on 6 boards. Overboarded · 6 public boards Last updated September 28, 2026
Time on boards
- Boards served
- 6
- Current seats
- 6
- Board service
- 11 years
- Director since
- 2024
11 years of board service in total across 6 boards, counting each seat separately. Longest: Spyre Therapeutics Inc., 2 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
NewAmsterdam Pharma Company N.V. June 4, 202599.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 20, 2026 | Freenome Inc. | Derivative conversion | +30,000 | — | — |
| Jan 7, 2026 | NewAmsterdam Pharma Company N.V. | Grant or award | +3,400 | — | — |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Option exercise | +30,000 | — | — |
| Jan 7, 2025 | NewAmsterdam Pharma Company N.V. | Grant or award | +6,960 | — | — |
Questions about Mark C. McKenna
What boards is Mark C. McKenna on?
Mark C. McKenna sits on the boards of BridgeBio Oncology Therapeutics Inc., Freenome Inc., Helix Acquisition Corp. III, NewAmsterdam Pharma Company N.V., Spyre Therapeutics Inc. and TCGX Acquisition Corp. II.
How long has Mark C. McKenna served on boards?
Our records show at least 11 years of board service across 6 boards, the earliest from 2024.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.